
    
      The primary objective is to determine the noninferiority in the early clinical response rate
      of 6 day oral TR-701 FA compared with that of 10-day oral linezolid treatment at the 48-72
      Hour Visit in the ITT analysis set in patients with ABSSSI.
    
  